

Biosimilars authorized in Canada as of December 3, 2018

Biosimilar	Reference Biologic Drug	Date of Authorization	Link to Summary Basis of Decision
ADMELOG insulin lispro	HUMALOG	2017	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00374
BASAGLAR insulin glargine	LANTUS	2015	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00281
BRENZYS etanercept	ENBREL	2016	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00333
ERELZI etanercept	ENBREL	2017	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00360
GRASTOFIL filgrastim	NEUPOGEN	2015	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00276
HADLIMA / HADLIMA PUSHTOUCH adalimumab	HUMIRA	2018	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00398
INFLECTRA infliximab	REMICADE	2014	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00253
REMSIMA infliximab	REMICADE	2014	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-result.php?term=REMSIMA
RENFLEXIS infliximab	REMICADE	2017	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00379

Biosimilar	Reference Biologic Drug	Date of Authorization	Link to Summary Basis of Decision
LAPELGA pegfilgrastim	NEULASTA	2018	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00396
MVASI bevacizumab	AVASTIN	2018	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00404
OMNITROPE™ somatropin	GENOTROPIN	2009	https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailOne.php?linkID=SBD00105

Additional Information:

Information about the regulation of [Biosimilars](#).

Health Canada's [Drug Product Database](#) contains product specific information including product monographs for drugs authorized in Canada.

[Regulatory Decision Summaries \(RDSs\)](#) briefly explain Health Canada's decision for drugs including biosimilars.

[Summary Basis of Decision \(SBD\)](#) documents explain in further detail why Health Canada authorized certain drugs for sale in Canada. SBD documents are available for biosimilars authorized in Canada.

[Submissions Under Review \(SUR\)](#) lists certain drug submissions currently under review by Health Canada.

The [Canada Vigilance Adverse Reaction Online Database](#) contains information about suspected adverse reactions (also known as side effects) to health products.